Gilead Sciences Inc. (GILD)
GILD Q2 Earnings Call Raises Outlook on HIV and PrEP Strength
Gilead raises its 2026 base-business outlook as HIV and PrEP momentum strengthens, while Trodelvy growth and two potential launches shape the second half.
GILD Q2 Earnings Beat on HIV and Trodelvy Growth, Product Sales Outlook Raised
GILD beats Q2 revenue estimates as HIV sales fuel growth, while acquisition charges cause a loss. Higher HIV guidance and pipeline progress support momentum.
Gilead Sciences, Inc. (GILD) Q2 2026 Earnings Call Transcript
Gilead Sciences, Inc. (GILD) Q2 2026 Earnings Call Transcript
Gilead Sciences Q2 Earnings Call Highlights
Gilead Sciences NASDAQ: GILD reported second-quarter 2026 base business sales growth of 10% year over year to $7.6 billion, supported by HIV treatments and prevention products, Trodelvy in oncology and Livdelzi in liver disease. The company raised its full-year base business sales outlook and increased its expected HIV growth rate, while reporting a quarterly non-GAAP loss driven by acquisition-related research and development charges.
Compared to Estimates, Gilead (GILD) Q2 Earnings: A Look at Key Metrics
The headline numbers for Gilead (GILD) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Gilead Sciences (GILD) Reports Q2 Loss, Beats Revenue Estimates
Gilead Sciences (GILD) came out with a quarterly loss of $6.75 per share versus the Zacks Consensus Estimate of a loss of $7.07. This compares to earnings of $2.01 per share a year ago.
Gilead Sciences Swings to Loss on R&D Costs as HIV-Drug Sales Lift Revenue
The biopharmaceutical company lowered its full-year forecast for Veklury after sales of the Covid-19 treatment fell 81% in the second quarter.
Seeking Clues to Gilead (GILD) Q2 Earnings? A Peek Into Wall Street Projections for Key Metrics
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Gilead (GILD), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2026.
Is Most-Watched Stock Gilead Sciences, Inc. (GILD) Worth Betting on Now?
Zacks.com users have recently been watching Gilead (GILD) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Gilead: Buy The Distortion Before Q2 Clears It Up
Gilead Sciences is a buy, as a temporary $11.5 billion IPR&D charge distorts optics but not fundamentals. GILD's HIV franchise is growing 8% with patent protection through 2036 and up to seven new launches by 2033. Oncology inflection is underway, led by Trodelvy's first-line expansion and strategic acquisitions building a next-gen pipeline.
Gilead to Report Q2 Earnings: How Should You Play the Stock Now?
GILD heads into Q2 earnings with HIV franchise strength, rising Yeztugo expectations and oncology progress, even as Cell Therapy faces competitive pressure.
Gilead Sciences (GILD) Laps the Stock Market: Here's Why
Gilead Sciences (GILD) reached $134.32 at the closing of the latest trading day, reflecting a +2.91% change compared to its last close.
